Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03913234 | Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients | unknown | Phase 1 / Phase 2 | 95 | Yonsei UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05150535 | One Week Adjuvant Radiotherapy for Breast Cancer | unknown | N/A | 100 | Sohag UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT04605575 |
| Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer |
| unknown |
| Phase 2 |
| 208 |
| Sun Yat-sen UniversityOTHER |
| 1 |
| Apr 26, 2022 |
| clinicaltrials |
| NCT05346107 | PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer | unknown | Phase 2 | 100 | Xijing HospitalOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05346861 | Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab | unknown | Phase 3 | 240 | Fudan UniversityOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT03630913 | Sentinel Lymph Node After Neoadjuvant Chemotherapy in Breast Carcinoma(GANEA3) | unknown | N/A | 385 | Institut Cancerologie de l'OuestOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT03251313 | PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients | unknown | Phase 1 | 31 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04192903 | Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer | unknown | Phase 2 | 55 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04609215 | ImmunoBreast - A Phase Ib Study | unknown | Phase 1 / Phase 2 | 20 | Henrik DitzelOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04634747 | Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer | unknown | Phase 2 | 53 | OncoPep, Inc.INDUSTRY | 0 | Apr 20, 2022 | clinicaltrials |
| NCT04745975 | Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer | unknown | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05334810 | DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer | unknown | Phase 2 | 191 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Apr 19, 2022 | clinicaltrials |
| NCT04457700 | CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC | unknown | — | 218 | Peking UniversityOTHER | 1 | Apr 18, 2022 | clinicaltrials |
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | unknown | Phase 1 | 219 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05288127 | Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature | unknown | Phase 2 | 55 | University of MalayaOTHER | 1 | Mar 21, 2022 | clinicaltrials |
| NCT05280288 | Effect of the App Bone@BC Version 4.0 Under the Follow-up for Patients With Early Breast Cancer | unknown | N/A | 120 | Rigshospitalet, DenmarkOTHER | 0 | Mar 15, 2022 | clinicaltrials |
| NCT03145961 | A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients(c-TRAK-TN) | unknown | Phase 2 | 208 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT05189067 | Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer | unknown | Phase 2 / Phase 3 | 190 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT05089643 | Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer | unknown | Phase 2 | 35 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT05154396 | Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer | unknown | Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 0 | Dec 13, 2021 | clinicaltrials |
| NCT05151224 | Circulating microRNA 21 Expression Level Before and After Neoadjuvant Systemic Therapy in Breast Carcinoma | unknown | — | 40 | Ain Shams UniversityOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT03238495 | Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer(HERMET) | unknown | Phase 2 | 100 | Qamar KhanOTHER | 1 | Dec 7, 2021 | clinicaltrials |
| NCT03381092 | Sentinel Lymph Node Biopsy in Clinically Node-negative Early Breast Cancer Patients After Neoadjuvant Chemotherapy | unknown | — | 348 | Peking UniversityOTHER | 1 | Nov 29, 2021 | clinicaltrials |
| NCT05134519 | RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer | unknown | Phase 2 | 20 | Xijing HospitalOTHER | 0 | Nov 26, 2021 | clinicaltrials |
| NCT05103917 | A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC | unknown | Phase 1 / Phase 2 | 24 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Nov 2, 2021 | clinicaltrials |
| NCT05088057 | Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer | unknown | Phase 2 | 30 | Aiping ShiOTHER | 1 | Oct 21, 2021 | clinicaltrials |
| NCT05068141 | A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC) | unknown | Phase 2 | 79 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 15, 2021 | clinicaltrials |
| NCT05076695 | Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer(NeoTPPF) | unknown | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Oct 13, 2021 | clinicaltrials |
| NCT02909426 | The Mammography and Ultrasonography STudy for Breast Cancer Screening Effectiveness(MUST-BE) | unknown | — | 11,880 | Soonchunhyang University HospitalOTHER | 1 | Oct 7, 2021 | clinicaltrials |
| NCT05063643 | Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude | unknown | — | 132 | Affiliated Hospital of Qinghai UniversityOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT03655353 | A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer(Affibody-3) | unknown | N/A | 160 | Henrik LindmanOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT05045287 | Hypofractionated Post Mastectomy Radiation With Two-Stage Expander/Implant Reconstruction | unknown | N/A | 57 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03521245 | Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer | unknown | — | 40 | OmicsWay Corp.INDUSTRY | 2 | Sep 14, 2021 | clinicaltrials |
| NCT05019365 | Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy | unknown | — | 60 | University of GlasgowOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04452370 | Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer | unknown | Phase 2 | 100 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT04913571 | Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study(TEMPLATE) | unknown | Phase 2 | 265 | Fudan UniversityOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04024800 | Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer(NSABP FB-14) | unknown | Phase 2 | 29 | NuGenerex Immuno-OncologyINDUSTRY | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04760431 | TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN) | unknown | Phase 2 | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04907344 | Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | unknown | Phase 2 / Phase 3 | 420 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 28, 2021 | clinicaltrials |
| NCT04809779 | PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC(NeoPD1TNBC) | unknown | Phase 2 | 49 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 22, 2021 | clinicaltrials |
| NCT04170595 | Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection | unknown | Phase 1 / Phase 2 | 132 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT03698383 | Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer | unknown | Phase 2 | 15 | Korean Cancer Study GroupOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT04750382 | A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer | unknown | Phase 1 / Phase 2 | 31 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04300829 | Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients(CICA-RT) | unknown | Phase 3 | 248 | Centre Leon BerardOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04676997 | Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) | unknown | Phase 2 | 20 | Shandong Cancer Hospital and InstituteOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04669522 | Psychological Factors and Oncological Outcomes of Triple-negative Breast Cancer(PSY-ONC TNBC) | unknown | — | 50 | Pius-Hospital OldenburgOTHER | 0 | Dec 17, 2020 | clinicaltrials |
| NCT04609540 | Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC | unknown | — | 200 | Shandong Cancer Hospital and InstituteOTHER | 0 | Dec 16, 2020 | clinicaltrials |
| NCT04582955 | Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy | unknown | N/A | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 7, 2020 | clinicaltrials |
Data updated 23 days agoSource updated May 10, 2022source: clinicaltrials